You are viewing the site in preview mode

Skip to main content

Table 3 Cox univariate proportional-hazards analysis for filter clotting during first filter use

From: Continuous renal replacement therapy in COVID-19—associated AKI: adding heparin to citrate to extend filter life—a retrospective cohort study

Risk factor All patients p
(N = 238)
HR (95% CI)
Heparin use 0.37 (0.25–0.55) < 0.001
COVID-19 diagnosis 0.87 (0.55–1.38) 0.561
Age, per year increase 1.01 (1.00–1.03) 0.144
Male sex 1.28 (0.83–1.96) 0.266
D-dimer level,* per 1000 increase 1.01 (1.00–1.02) 0.003
Hemoglobin level 1.12 (1.04–1.21) 0.003
Platelet count, per 100,000 increase 1.00 (1.00–1.00) 0.299
BUN, per 10 increase 1.00 (0.95–1.04) 0.922
ACD-A 4–5 mmol/L vs. 2–3 mmol/L 0.82 (0.54–1.23) 0.331
Vasopressor use 0.93 (0.51–1.70) 0.826
Treatment modality 0.55 (0.27–1.14) 0.109
Obesity 1.09 (0.70–1.69) 0.703
  1. HR, hazard ratio; COVID-19, coronavirus disease 2019, BUN, blood urea nitrogen; ACD-A, anticoagulant citrate dextrose solution formula A
  2. *Value obtained closest to the initiation of renal replacement therapy (median 5990 ng/ml)
Back to article page

Critical Care

ISSN: 1364-8535